Affinium Pharmaceuticals (Austin, TX) a clinical-stage specialty pharmaceutical company focused on small molecule antibiotics targeting staph and MRSA infections, closed a $15M Series B financing. Participants include SV Life Sciences, Genesis Capital Partners, Forward Ventures and Ontario Emerging Technologies Fund.

Thanx for your patience as we catch-up.